Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Nautilus Biotechnology, Inc. (NAUT) had Consolidated Net Income/Loss of $-13.57M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-13.57M |
|
-- |
|
-- |
|
$15.47M |
|
$-15.47M |
|
$1.90M |
|
$-13.57M |
|
$-13.57M |
|
$-13.57M |
|
$-13.57M |
|
|
Consolidated Net Income/Loss |
$-13.57M |
$-13.57M |
|
$-15.47M |
|
$-14.16M |
|
126.31M |
|
126.31M |
|
$-0.11 |
|
$-0.11 |
|
| Balance Sheet Financials | |
$134.32M |
|
$3.62M |
|
$66.59M |
|
$200.91M |
|
$8.98M |
|
-- |
|
$22.79M |
|
$31.78M |
|
$169.14M |
|
$169.14M |
|
$169.14M |
|
126.31M |
|
| Cash Flow Statement Financials | |
$-38.32M |
|
$34.44M |
|
$0.11M |
|
$28.65M |
|
$24.88M |
|
$-3.77M |
|
$5.37M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
14.95 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-39.35M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-8.03% |
|
-8.03% |
|
-6.76% |
|
-8.03% |
|
$1.34 |
|
$-0.31 |
|
$-0.30 |
|